Lewy Body Dementia Treatment Market
Lewy Body Dementia Treatment Market Study by Cholinesterase Inhibitors, Antipsychotic Drugs, Carbidopa-Levodopa, Antidepressants, Benzodiazepine, and Modafinil from 2023 to 2033
Analysis of Lewy Body Dementia Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Lewy Body Dementia Treatment Market Outlook (2023 to 2033)
Worldwide demand for Lewy body dementia treatment accounts for a market value of US$ 4.7 billion in 2023. Across the study period (2023 to 2033), the global Lewy body dementia treatment market size is predicted to expand steadily at 6% CAGR and reach US$ 8.45 billion by the end of 2033.
The build-up of protein masses known as Lewy bodies in certain brain cells is the prime Lewy body dementia cause. It is most likely to affect people above 50 years of age and can also be synonymous with other neurodegenerative disorders. The rapidly expanding geriatric population around the world is necessitating the demand for advanced Lewy body dementia diagnosis and prognosis, which is slated to create new opportunities for companies operating in this space.
Increasing availability of Lewy body dementia support groups and Lewy body dementia treatment options are also slated to impact market development across the study period.
- Lewy body dementia life expectancy ranges between 2 to 20 years on average, while most people live for around 5 to 8 years after diagnosis.
Governments are launching initiatives to promote awareness regarding Lewy body dementia symptoms and improve Lewy body dementia care for all. Increasing public and private investments in Lewy body dementia research is also projected to increase the number of Lewy body dementia clinical trials over the next ten years.
- For instance, the U.S. has passed a law called the BOLD Infrastructure for Alzheimer’s Act, an initiative aimed at forming a public health model against Alzheimer’s disease and other dementias. The law was passed in December 2018 and sanctioned approx. US$ 100 million over a period of five years to enhance public education, launch dementia initiatives, and collect and distribute data related to cognitive decline.
Considering the high cost of certain Lewy body dementia treatment medications and Lewy body dementia treatment therapies, healthcare insurance providers, and governments are focusing on drafting new reimbursement policies that would improve Lewy body dementia treatment insurance coverage in the future. High costs of Lewy body dementia treatment and late diagnosis of the condition are anticipated to be the prime constraints limiting lewy body dementia treatment market growth scope through 2033.
| Report Attributes | Details |
|---|---|
| Lewy Body Dementia Treatment Market Size (2023) | US$ 4.7 Billion |
| Projected Market Value (2033F) | US$ 8.45 Billion |
| Global Market Growth Rate (2023 to 2033) | 6% CAGR |
| Leading Regional Market (2023) | North America |
| Key Companies Profiled | BioArctic AB; Eisai Co. Ltd.; Noven Pharmaceuticals Inc.; Eli Lilly and Company; Novartis AG; Pfizer Inc.; Mylan NV; Sumitomo Dainippon Pharma Co. Ltd.; Jazz Pharmaceuticals Inc.; Bayer AG; Allergan Plc.; Sanofi AG; Teva Pharmaceuticals; GlaxoSmithKline; Takeda Pharmaceutical Company Ltd.; Janssen Pharmaceuticals Inc.; Bausch Health Companies Inc.; Mallinckrodt Pharmaceuticals |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
How are Start-ups Trying to Maximize Their Business Scope in This Space?
“Capital Raise for Lewy Body Dementia Research Crucial for New Companies”
The need for a proper treatment for dementia has been around for years and with modern advancements in the healthcare industry, companies think can make dementia treatment a reality. Developing a treatment requires huge capital investment from the research to development and commercialization process and this is why incoming Lewy body dementia treatment providers are focusing on raising funds to finance their efforts in the future.
- In May 2023, Violet Therapeutics Inc., a pre-clinical stage company focusing on cellular connectome, announced that it had raised US$ 10.6 million in a seed financing round. Dementia Discovery Fund (DDF) led the round with the University of Tokyo Edge Capital Partners (UTEC) and participation from other investors.
Rising awareness regarding dementia and the immense scope of opportunity is pushing venture capital firms and healthcare investors to establish specialized funds to aid start-ups working on the treatment of dementia, which is slated to push more new healthcare companies to invest in dementia treatment going forward.
- In March 2023, EQT Life Sciences, a renowned healthcare investor based in the Netherlands, announced that it had closed its LSP Dementia Fund at approximately US$ 282.56 million, which is nearly US$ 100 million more than its initial target value. The fund is dedicated to investing in new companies working on bringing novel solutions for people affected with dementia.
- ESP Diagnostics, a United Kingdom-based start-up is focusing on developing a new early detection test for dementia with Lewy bodies and Parkinson’s disease. The extracellular synucleinopathic protein test is estimated to hit the European markets by the end of 2023.
Start-ups can benefit by learning more about aspects such as local supply, pricing trends, product standards, safety regulations, and new developments that have been discussed extensively in this Lewy body dementia treatment industry study by skilled analysts at Fact.MR, a market research and competitive intelligence provider.
Country-wise Insights
Rapidly aging population of the world makes it an oyster for Lewy body dementia treatment companies and allows them to expand their business anywhere. Investing in the United States, China, Germany, Japan, and Italy could offer a much better return on investment over the coming years.
What Makes the United States a Key Market for Lewy Body Dementia Treatment?
“High Focus on Neurodegenerative Disease Research”
The United States is home to some of the most prominent research programs focusing on neurology and neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. Supportive government initiatives, high private investments in neurology R&D, and the presence of key biotechnology and pharmaceutical companies are other factors that make the United States a moneymaking market for Lewy body dementia treatment providers.
Why is Japan a Leading Market for Lewy Body Dementia Treatment Providers?
“Prominent Presence of Senescent Demographic”
Japan’s rapidly aging population is neither a secret nor a surprise to anyone. The risk of dementia and other neurodegenerative diseases is much higher in a geriatric population as compared to a demographic that’s under the age of 50 and this is why Japan is a highly rewarding market for Lewy body dementia treatment companies going forward.
- As per an article published in The Japan Times in September 2022, people 75 years of age accounted for over 15% of the total population of the country for the first time in history. 29.1% of the population was also found to be over 65 years of age.
Efforts to improve elder care and the establishment of new dementia care centers in the country are projected to create new opportunities for established as well as incoming Lewy body dementia treatment providers through 2033.
- Shinobu Yamanaka, a Japanese woman diagnosed with early-onset Alzheimer’s opened up a dementia care facility called Day Service Happy in the Kochi prefecture of Japan.
The problem of dementia is a severe one in Japan and people like Shinobu Yamanaka taking the initiative to deal with it themselves and help others to show how important it is to have a proper dementia treatment to help these people in the best way possible.
Which European Countries Should Lewy Body Dementia Treatment Providers Target?
“Italy, Portugal, Germany, and Greece Prime European Markets”
European countries are home to some of the most rapidly expanding geriatric populations in the world and Italy tops this chart at present. Tackling the dementia problem in Italy is crucial to its economic growth in the future as the country lost a good chunk of its working population in the COVID-19 pandemic.
- As per a news article published in March 2023, people of 65 years or more age accounted for around 23% of the total population of Italy and this made it the country with the highest share of 65+ year-old people in the European Union.
Similarly, Greece is also facing severe economic issues owing to its increasing aging population and this could prove to be a golden opportunity for Lewy body dementia treatment providers looking to enter the European markets. Germany, Portugal, and Bulgaria are among other noteworthy spaces that companies could target to establish their stronghold in the European region going forward.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Category-wise Insights
This Fact.MR research survey analyzes the Lewy body dementia treatment market based on drug type, indication, distribution channel, and region. Cholinesterase inhibitors are estimated to lead the global revenue generation charge over the next ten years with most sales accounted for by hospital pharmacies.
Which Lewy Body Dementia Treatment Drug is Most Popular?
“Cholinesterase Inhibitors Account for Leading Market Share”
Minimal side effects associated with the use of cholinesterase inhibitor drugs make them the most widely used medication for the treatment of Lewy body dementia. After cholinesterase inhibitors, antipsychotic drugs are the second-most used medications to help people suffering from Lewy body dementia.
Competitive Landscape
Product innovation is of the essence for Lewy body dementia treatment companies and this is why they are projected to invest heavily in R&D efforts across the study period and beyond. Lewy body dementia treatment drug providers are also estimated to focus on new launches to improve their sales potential in the long run.
- In January 2023, Biogen Inc., a renowned American biotechnology organization, announced that its marketing authorization application (MAA) for lecanemab was accepted by the European Medicines Agency (EMA). Lecanemab was also approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease on 6th January 2023.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Key Segments of Lewy Body Dementia Treatment Industry Research
-
By Drug Type:
- Cholinesterase Inhibitors
- Antipsychotic Drugs
- Carbidopa-Levodopa
- Antidepressants
- Benzodiazepine
- Modafinil
-
By Indication:
- Dementia with Lewy Bodies (DLB)
- Alzheimer’s Disease
- Parkinson’s Disease
-
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
-
By Region:
- North America
- Latin America
- Europe
- APAC
- MEA
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Key Success Factors
- 5. Global Market Demand (in Value or Size in US$ Mn) Analysis 2018 to 2022 and Forecast, 2023 to 2033
- 6. Market Background
- 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Drug Type
- 7.1. Cholinesterase Inhibitors
- 7.2. Antipsychotic Drugs
- 7.3. Carbidopa-Levodopa
- 7.4. Antidepressants
- 7.5. Benzodiazepine
- 7.6. Modafinil
- 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Indication
- 8.1. Dementia with Lewy Bodies (DLB)
- 8.2. Parkinson’s Disease (PD)
- 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Distribution Channel
- 9.1. Hospital Pharmacies
- 9.2. Retail Pharmacies
- 9.3. Drug Stores
- 9.4. Online Pharmacies
- 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Europe
- 10.4. Middle East and Africa (MEA)
- 10.5. East Asia
- 10.6. South Asia
- 10.7. Oceania
- 11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 14. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 16. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 17. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 18. Emerging Countries Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 19. Competition Analysis
- 19.1. Axovant Sciences Ltd.
- 19.2. BioArctic AB
- 19.3. Eisai Co., Ltd.
- 19.4. Sumitomo Dainippon Pharma Co., Ltd.
- 19.5. Jazz Pharmaceuticals, Inc.
- 19.6. Immungenetics AG
- 19.7. Noven Pharmaceuticals, Inc.
- 19.8. Eli Lilly and Company
- 19.9. Novartis AG
- 19.10. Pfizer Inc.
- 19.11. Bayer AG
- 19.12. Mylan NV
- 19.13. Sanofi AG
- 19.14. Teva Pharmaceutical Industries Limited
- 19.15. GlaxoSmithKline plc
- 19.16. Takeda Pharmaceutical Company Limited
- 19.17. Allergan plc
- 19.18. Janssen Pharmaceuticals, Inc.
- 19.19. Bausch Health Companies Inc.
- 19.20. Mallinckrodt Pharmaceuticals
- 20. Assumptions and Acronyms Used
- 21. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01 : Global Market Pipeline Assessment – Clinical Trials
Table 02: Global Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Drug Type
Table 03: Global Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Indication
Table 04: Global Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Distribution Channel
Table 05: Global Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Region
Table 06: North America Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Country
Table 07: North America Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Indication
Table 08: North America Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Drug Type
Table 09: North America Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Distribution Channel
Table 10: Latin America Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Country
Table 11: Latin America Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Indication
Table 12: Latin America Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Drug Type
Table 13: Latin America Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Distribution Channel
Table 14: Europe Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Country
Table 15: Europe Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Indication
Table 16: Europe Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Drug Type
Table 17: Europe Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Distribution Channel
Table 18: South Asia Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Country
Table 19: South Asia Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Indication
Table 20: South Asia Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Drug Type
Table 21: South Asia Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Distribution Channel
Table 22: East Asia Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Country
Table 23: East Asia Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Indication
Table 24: East Asia Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Drug Type
Table 25: East Asia Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Distribution Channel
Table 26: Oceania Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Country
Table 27: Oceania Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Indication
Table 28: Oceania Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Drug Type
Table 29: Oceania Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Distribution Channel
Table 30: MEA Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Country
Table 31: MEA Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Indication
Table 32: MEA Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Drug Type
Table 33: MEA Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Distribution Channel
Table 34: China Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Drug Type
Table 35: China Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Indication
Table 36: China Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Distribution Channel
Table 37: India Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Drug Type
Table 38: India Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Indication
Table 39: India Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Distribution Channel
Table 40: Brazil Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Drug Type
Table 41: Brazil Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Indication
Table 42: Brazil Market size (US$ Mn) Analysis 2018 to 2022 and forecast 2023 to 2033, By Distribution Channel
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Number of clinical trials for Lewy Body Dementia, By Phase
Figure 02: Number of clinical trials for Lewy Body Dementia, By Region
Figure 03: Global Market Value (US$ Mn) & Y-o-Y Growth (%), 2018 to 2033
Figure 04: Global Market Absolute $ Opportunity (US$ Mn), 2022 to 2033
Figure 05: Share of Elderly (65+) Population by Region, 2022
Figure 06: Comparison of Elderly Population with GDP per Capita, 2021
Figure 07: GDP (US$ Trillion) and Healthcare Expenditure % (2022)
Figure 08: Global Market Share Analysis (%) By Drug Type, 2023 & 2033
Figure 09: Global Market Y-o-Y Growth (%) By Drug Type, 2023 to 2033
Figure 10: Global Market Value, 2018 to 2022, Cholinesterase Inhibitors
Figure 11: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Cholinesterase Inhibitors
Figure 12: Global Market Value, 2018 to 2022, Antipsychotic Drugs
Figure 13: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Antipsychotic Drugs
Figure 14: Global Market Value, 2018 to 2022, Carbidopa-Levodopa
Figure 15: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Carbidopa-Levodopa
Figure 16: Global Market Value, 2018 to 2022, Antidepressants
Figure 17: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Antidepressants
Figure 18: Global Market Value, 2018 to 2022, Benzodiazepine
Figure 19: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Benzodiazepine
Figure 20: Global Market Value, 2018 to 2022, Modafinil
Figure 21: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Modafinil
Figure 22: Global Market Attractiveness Analysis By Drug Type, 2023 to 2033
Figure 23: Global Market Share Analysis (%) By Indication, 2023 & 2033
Figure 24: Global Market Y-o-Y Growth (%) By Indication, 2023 to 2033
Figure 25: Global Market Value, 2018 to 2022, Dementia with Lewy Bodies (DLB)
Figure 26: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Dementia with Lewy Bodies (DLB)
Figure 27: Global Market Value, 2018 to 2022, Parkinson’s Disease (PD)
Figure 28: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Parkinson’s Disease (PD)
Figure 29: Global Market Attractiveness Analysis By Indication, 2023 to 2033
Figure 30: Global Market Share Analysis (%) By Distribution Channel, 2023 & 2033
Figure 31: Global Market Y-o-Y Growth (%) By Distribution Channel, 2023 to 2033
Figure 32: Global Market Value, 2018 to 2022, Hospital Pharmacies
Figure 33: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Hospital Pharmacies
Figure 34: Global Market Value, 2018 to 2022, Retail Pharmacies
Figure 35: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Retail Pharmacies
Figure 36: Global Market Value, 2018 to 2022, Drug Stores
Figure 37: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Drug Stores
Figure 38: Global Market Value, 2018 to 2022, Online Pharmacies
Figure 39: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Online Pharmacies
Figure 40: Global Market Attractiveness Analysis By Distribution Channel, 2023 to 2033
Figure 41: Global Market Share Analysis (%) By Region, 2023 & 2033
Figure 42: Global Market Y-o-Y Growth (%) By Region, 2023 to 2033
Figure 43: Global Market Value, 2018 to 2022, North America
Figure 44: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, North America
Figure 45: Global Market Value, 2018 to 2022, Latin America
Figure 46: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Latin America
Figure 47: Global Market Value, 2018 to 2022, Europe
Figure 48: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Europe
Figure 49: Global Market Value, 2018 to 2022, East Asia
Figure 50: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, East Asia
Figure 51: Global Market Value, 2018 to 2022, South Asia
Figure 52: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, South Asia
Figure 53: Global Market Value, 2018 to 2022, Oceania
Figure 54: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Oceania
Figure 55: Global Market Value, 2018 to 2022, Middle East & Africa
Figure 56: Global Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Middle East & Africa
Figure 57: Global Market Attractiveness Analysis By Region, 2023 to 2033
Figure 58: North America Market Value Share, By Country
Figure 59: North America Market Value Share, By Indication (2022 & 2033)
Figure 60: North America Market Value Share, By Drug Type (2022 & 2033)
Figure 61: North America Market Value Share, By Distribution Channel (2022 & 2033)
Figure 62: North America Market Size (US$ Mn) Analysis, 2018 to 2022
Figure 63: North America Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033
Figure 64: North America Market Value, 2018 to 2022, Dementia with Lewy Bodies (DLB)
Figure 65: North America Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Dementia with Lewy Bodies (DLB)
Figure 66: North America Market Value, 2018 to 2022, Parkinson’s Disease (PD)
Figure 67: North America Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Parkinson’s Disease (PD)
Figure 68: North America Market Attractiveness Analysis, By Country (2018 to 2033)
Figure 69: North America Market Attractiveness Analysis, By Drug Type (2018 to 2033)
Figure 70: North America Market Attractiveness Analysis, By Indication (2018 to 2033)
Figure 71: North America Market Attractiveness Analysis, By Distribution Channel (2018 to 2033)
Figure 72: Latin America Market Value Share, By Country
Figure 73: Latin America Market Value Share, By Indication (2022 & 2033)
Figure 74: Latin America Market Value Share, By Drug Type (2022 & 2033)
Figure 75: Latin America Market Value Share, By Distribution Channel (2022 & 2033)
Figure 76: Latin America Market Size (US$ Mn) Analysis, 2018 to 2022
Figure 77: Latin America Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033
Figure 78: Latin America Market Value, 2018 to 2022, Dementia with Lewy Bodies (DLB)
Figure 79: Latin America Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Dementia with Lewy Bodies (DLB)
Figure 80: Latin America Market Value, 2018 to 2022, Parkinson’s Disease (PD)
Figure 81: Latin America Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Parkinson’s Disease (PD)
Figure 82: Latin America Market Attractiveness Analysis, By Country (2018 to 2033)
Figure 83: Latin America Market Attractiveness Analysis, By Drug Type (2018 to 2033)
Figure 84: Latin America Market Attractiveness Analysis, By Indication (2018 to 2033)
Figure 85: Latin America Market Attractiveness Analysis, By Distribution Channel (2018 to 2033)
Figure 86: Europe Market Value Share, By Country
Figure 87: Europe Market Value Share, By Indication (2022 & 2033)
Figure 88: Europe Market Value Share, By Drug Type (2022 & 2033)
Figure 89: Europe Market Value Share, By Distribution Channel (2022 & 2033)
Figure 90: Europe Market Size (US$ Mn) Analysis, 2018 to 2022
Figure 91: Europe Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033
Figure 92: Europe Market Value, 2018 to 2022, Dementia with Lewy Bodies (DLB)
Figure 93: Europe Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Dementia with Lewy Bodies (DLB)
Figure 94: Europe Market Value, 2018 to 2022, Parkinson’s Disease (PD)
Figure 95: Europe Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Parkinson’s Disease (PD)
Figure 96: Europe Market Attractiveness Analysis, By Country (2018 to 2033)
Figure 97: Europe Market Attractiveness Analysis, By Drug Type (2018 to 2033)
Figure 98: Europe Market Attractiveness Analysis, By Indication (2018 to 2033)
Figure 99: Europe Market Attractiveness Analysis, By Distribution Channel (2018 to 2033)
Figure 100: South Asia Market Value Share, By Country
Figure 101: South Asia Market Value Share, By Indication (2022 & 2033)
Figure 102: South Asia Market Value Share, By Drug Type (2022 & 2033)
Figure 103: South Asia Market Value Share, By Distribution Channel (2022 & 2033)
Figure 104: South Asia Market Size (US$ Mn) Analysis, 2018 to 2022
Figure 105: South Asia Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033
Figure 106: South Asia Market Value, 2018 to 2022, Dementia with Lewy Bodies (DLB)
Figure 107: South Asia Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Dementia with Lewy Bodies (DLB)
Figure 108: South Asia Market Value, 2018 to 2022, Parkinson’s Disease (PD)
Figure 109: South Asia Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Parkinson’s Disease (PD)
Figure 110: South Asia Market Attractiveness Analysis, By Country (2018 to 2033)
Figure 111: South Asia Market Attractiveness Analysis, By Drug Type (2018 to 2033)
Figure 112: South Asia Market Attractiveness Analysis, By Indication (2018 to 2033)
Figure 113: South Asia Market Attractiveness Analysis, By Distribution Channel (2018 to 2033)
Figure 114: East Asia Market Value Share, By Country
Figure 115: East Asia Market Value Share, By Indication (2022 & 2033)
Figure 116: East Asia Market Value Share, By Drug Type (2022 & 2033)
Figure 117: East Asia Market Value Share, By Distribution Channel (2022 & 2033)
Figure 118: East Asia Market Size (US$ Mn) Analysis, 2018 to 2022
Figure 119: East Asia Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033
Figure 120: East Asia Market Value, 2018 to 2022, Dementia with Lewy Bodies (DLB)
Figure 121: East Asia Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Dementia with Lewy Bodies (DLB)
Figure 122: East Asia Market Value, 2018 to 2022, Parkinson’s Disease (PD)
Figure 123: East Asia Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Parkinson’s Disease (PD)
Figure 124: East Asia Market Attractiveness Analysis, By Country (2018 to 2033)
Figure 125: East Asia Market Attractiveness Analysis, By Drug Type (2018 to 2033)
Figure 126: East Asia Market Attractiveness Analysis, By Indication (2018 to 2033)
Figure 127: East Asia Market Attractiveness Analysis, By Distribution Channel (2018 to 2033)
Figure 128: Oceania Market Value Share, By Country
Figure 129: Oceania Market Value Share, By Indication (2022 & 2033)
Figure 130: Oceania Market Value Share, By Drug Type (2022 & 2033)
Figure 131: Oceania Market Value Share, By Distribution Channel (2022 & 2033)
Figure 132: Oceania Market Size (US$ Mn) Analysis, 2018 to 2022
Figure 133: Oceania Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033
Figure 134: Oceania Market Value, 2018 to 2022, Dementia with Lewy Bodies (DLB)
Figure 135: Oceania Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Dementia with Lewy Bodies (DLB)
Figure 136: Oceania Market Value, 2018 to 2022, Parkinson’s Disease (PD)
Figure 137: Oceania Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Parkinson’s Disease (PD)
Figure 138: Oceania Market Attractiveness Analysis, By Country (2018 to 2033)
Figure 139: Oceania Market Attractiveness Analysis, By Drug Type (2018 to 2033)
Figure 140: Oceania Market Attractiveness Analysis, By Indication (2018 to 2033)
Figure 141: Oceania Market Attractiveness Analysis, By Distribution Channel (2018 to 2033)
Figure 142: MEA Market Value Share, By Country
Figure 143: MEA Market Value Share, By Indication (2022 & 2033)
Figure 144: MEA Market Value Share, By Drug Type (2022 & 2033)
Figure 145: MEA Market Value Share, By Distribution Channel (2022 & 2033)
Figure 146: MEA Market Size (US$ Mn) Analysis, 2018 to 2022
Figure 147: MEA Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033
Figure 148: MEA Market Value, 2018 to 2022, Dementia with Lewy Bodies (DLB)
Figure 149: MEA Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Dementia with Lewy Bodies (DLB)
Figure 150: MEA Market Value, 2018 to 2022, Parkinson’s Disease (PD)
Figure 151: MEA Market Value, Forecast & Y-o-Y Growth (%), 2023 to 2033, Parkinson’s Disease (PD)
Figure 152: MEA Market Attractiveness Analysis, By Country (2018 to 2033)
Figure 153: MEA Market Attractiveness Analysis, By Drug Type (2018 to 2033)
Figure 154: MEA Market Attractiveness Analysis, By Indication (2018 to 2033)
Figure 155: MEA Market Attractiveness Analysis, By Distribution Channel (2018 to 2033)
Figure 156: Global Market Value Proportion Analysis, By Emerging Countries, 2018
Figure 157: Market, Global Vs. Country Growth Y-o-Y (%) Comparison, 2018 to 2033
Figure 158: China Market Value Analysis (US$ Mn), 2013 to 2022
Figure 159: China Market Value Forecast (US$ Mn), 2018 to 2033
Figure 160: China Market Attractiveness Analysis, By Drug Type (2018 to 2033)
Figure 161: China Market Attractiveness Analysis, By Indication (2018 to 2033)
Figure 162: China Market Attractiveness Analysis, By Distribution Channel (2018 to 2033)
Figure 163: India Market Value Analysis (US$ Mn), 2013 to 2022
Figure 164: China Market Value Forecast (US$ Mn), 2018 to 2033
Figure 165: India Market Attractiveness Analysis, By Drug Type (2018 to 2033)
Figure 166: India Market Attractiveness Analysis, By Indication (2018 to 2033)
Figure 167: India Market Attractiveness Analysis, By Distribution Channel (2018 to 2033)
Figure 168: Brazil Market Value Analysis (US$ Mn), 2013 to 2022
Figure 169: Brazil Market Value Forecast (US$ Mn), 2018 to 2033
Figure 170: Brazil Market Attractiveness Analysis, By Drug Type (2018 to 2033)
Figure 171: Brazil Market Attractiveness Analysis, By Indication (2018 to 2033)
Figure 172: Brazil Market Attractiveness Analysis, By Distribution Channel (2018 to 2033)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the Lewy body dementia treatment market in 2023?
The global Lewy body dementia treatment market is estimated at US$ 4.7 billion in 2023.
What is the projected market value for 2033?
Revenue from Lewy body dementia treatment is forecasted to reach US$ 8.45 billion by 2033.
At what pace will the global market expand in the future?
Demand for Lewy body dementia treatment is projected to rise at 6% CAGR from 2023 to 2033.
What is the longest one can live with Lewy body dementia?
Average life expectancy for people with Lewy body dementia is between 2 to 20 years.
Who is at high risk for Lewy body dementia?
People above 50 years of age and those with a family history of Parkinson’s disease are the most at risk of Lewy body dementia.
What are the current treatments for Lewy body dementia?
Cholinesterase inhibitors and antipsychotic drugs are widely used for Lewy body dementia treatment.
Which are the top companies in the market for Lewy body dementia treatment?
Novartis AG, Pfizer Inc., Mylan NV, and Sumitomo Dainippon Pharma Co. Ltd. are renowned companies in this business.
Lewy Body Dementia Treatment Market